Biological molecules are increasingly becoming a part of the therapeutics portfolio that has
been either recently approved for marketing or those that are in the pipeline of several …

Abstract In 1989, Manning, Patel, and Borchardt wrote a review of protein stability (Manning
et al., Pharm. Res. 6: 903–918, 1989), which has been widely referenced ever since. At the …

Animal testing is used in pharmaceutical and industrial research to predict human toxicity,
and yet analysis suggests that animal models are poor predictors of drug safety in humans …

Nanobodies (Nbs), the variable domains of camelid heavy chain-only antibodies, are a
promising class of therapeutics or in vivo imaging reagents entering the clinic. They possess …

All protein therapeutics have the potential to be immunogenic. Several factors, including
patient characteristics, disease state, and the therapy itself, influence the generation of an …

With almost 20 million new cases per year, cancer constitutes one of the most important
challenges for public health systems. Unlike traditional chemotherapy, targeted anti-cancer …

Abstract Background Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are novel agents
for type 2 diabetes treatment, offering glucose‐dependent insulinotropic effects, reduced …

Protein therapeutics have drastically changed the landscape of treatment for many diseases
by providing a regimen that is highly specific and lacks many off-target toxicities. The clinical …

An evaluation of potential antibody formation to biologic therapeutics during the course of
nonclinical safety studies and its impact on the toxicity profile is expected under current …

Immunomodulatory biologics, which render their therapeutic effects by modulating or
harnessing immune responses, have proven their therapeutic utility in several complex …